Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Insider Sells 3,114 Shares of Stock

Key Points

• Jared Gollob, an insider at Kymera Therapeutics, sold 3,114 shares at an average price of $60.00, totaling $186,840, which reduced his holdings by 2.56% to 118,359 shares.
• Kymera Therapeutics' stock price decreased by 2.7% to $58.26, with a trading volume of 522,130 shares, compared to its average volume of 754,344 shares.
• The company's recent earnings report showed a significant decline in revenue, down 55.1% year-over-year, with reported earnings of ($0.95) per share against a consensus estimate of ($0.83).

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Jared Gollob sold 3,114 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $60.00, for a total value of $186,840.00. Following the completion of the transaction, the insider directly owned 118,359 shares of the company's stock, valued at $7,101,540. This represents a 2.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kymera Therapeutics Stock Down 2.7%

Shares of NASDAQ:KYMR traded down $1.63 during trading on Tuesday, hitting $58.26. The stock had a trading volume of 522,130 shares, compared to its average volume of 754,344. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $60.00. The company has a market capitalization of $4.17 billion, a PE ratio of -16.79 and a beta of 2.26. The firm's fifty day moving average is $47.32 and its 200 day moving average is $40.52.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to analysts' expectations of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business's quarterly revenue was down 55.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.58) EPS. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several recent research reports. Wells Fargo & Company cut their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, June 26th. Wall Street Zen downgraded Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. B. Riley upgraded Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price on the stock in a research note on Wednesday, July 30th. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. Finally, Barclays assumed coverage on Kymera Therapeutics in a research note on Wednesday, September 17th. They set an "overweight" rating and a $60.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $61.26.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Siren L.L.C. raised its holdings in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after purchasing an additional 270,580 shares during the period. Rhumbline Advisers raised its holdings in Kymera Therapeutics by 9.0% during the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after acquiring an additional 5,771 shares during the period. Farther Finance Advisors LLC raised its holdings in Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after acquiring an additional 540 shares during the period. GAMMA Investing LLC raised its holdings in Kymera Therapeutics by 3,851.5% during the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after acquiring an additional 6,509 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company's stock valued at $110,000 after acquiring an additional 343 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.